Why is "Rituximab" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-04 14:54:12
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Rituximab entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-04 and was most recently seen on 2026-07-04.
Wikipedia Overview
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer, as well as for prevention and/or treatment of antibody-mediated rejection of organ transplants.
It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion.
Related Topics
Trending Topic Today
Search Interest Perspective
-
Phase III TRIANGLE trial: Ibrutinib-containing therapy + rituximab maintenance in MCL - Lymphoma Hub
-
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis - The New England Journal of Medicine
-
FDA Approves Rituximab Biosimilar for Hematologic Malignancies - OncLive
-
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma - Nature
-
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase - The Lancet
-
Kidney Compass: Rituximab Cuts Relapse Risk in MCD, FSGS in TURING Trial - HCPLive
-
Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature - Cureus
-
Rituximab Displays Long-Term Effectiveness for Relapsing MS - NeurologyLive
-
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus - ScienceDirect.com
-
Study Supports Use of Annual Rituximab Maintenance Dose After Multiple Sclerosis Remission - Neurology Today
-
Rituximab-Associated Colitis: An Unusual Case... : American Journal of Gastroenterology - Lippincott Home
-
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies - Targeted Oncology
-
Rituximab Use and the Increased Risk of Reactivation of Latent Tuberculosis? - Ovid
-
Zanubrutinib/Rituximab Improves PFS in Frontline Mantle Cell Lymphoma - CancerNetwork
-
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma - Wiley Online Library
-
Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45% - The American Journal of Managed Care
-
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemotherapy in MCL - OncLive
-
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial - Nature
-
Rituximab Noninferior to Ocrelizumab in Newly Diagnosed Relapsing MS, Head-to-Head Trial Finds - NeurologyLive
-
Loncastuximab Tesirine Plus Rituximab Meets PFS End Point in R/R DLBCL - Targeted Oncology
-
Fixed-Duration Pirtobrutinib Plus Venetoclax/Rituximab Yields PFS Advantage in R/R CLL/SLL - OncLive
-
Rituximab Associated With Achieving No Evidence of Disease Activity in MS - The American Journal of Managed Care
-
Epcoritamab Plus Lenalidomide and Rituximab Shows Consistent Efficacy Across R/R Follicular Lymphoma Subgroups - OncLive
-
EC approves epcoritamab in combination with lenalidomide + rituximab for R/R FL - Lymphoma Hub
-
Acalabrutinib May Weaken Rituximab’s Efficacy in CLL - The American Journal of Managed Care
-
Why Clinicians May Consider Obinutuzamab Over Rituximab in Follicular Lymphoma - The American Journal of Managed Care
-
Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies - Frontiers
-
Phase III SOUNDTRACK-F1 trial: Surovatamig + rituximab in previously untreated FL - Lymphoma Hub
-
Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial | Leukemia - Nature
-
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS - The American Journal of Managed Care
-
Rituximab Therapy for Fibrillary Glomerulonephritis in an Older Adult With Advanced Chronic Kidney Disease - Cureus
-
Ravulizumab's Effective and Safe in AQP4+ NMOSD Regardless of Prior Rituximab Use - NeurologyLive
-
Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL - OncLive
-
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial - The Lancet
-
Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1 - Pharmacy Times
-
Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report - Frontiers
-
Epcoritamab Plus Lenalidomide/Rituximab Wins EU Approval for R/R Follicular Lymphoma - OncLive
-
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial - The Lancet
-
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma - Managed Healthcare Executive
-
Case 2: Follicular Lymphoma With Relapse After Rituximab Monotherapy - The ASCO Post
-
Dose-Adjusted EPOCH Plus Tafasitamab ± Rituximab Yields MRD Negativity in Newly Diagnosed, Ph– B-ALL - OncLive
-
B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic Diseases - Wiley & Sons
-
Commentary: Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report - Frontiers
-
Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia | Leukemia - Nature
-
Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy - Frontiers
-
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market - Business Wire
-
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL - The ASCO Post
-
Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study - Cureus
-
Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma - OncLive
-
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
-
Montelukast Prophylaxis Reduces Rituximab Infusion Reactions in Oncology Patients - Pharmacy Times
-
Rituximab May Lower Immunoglobulin A Vasculitis Renal Complications - Medscape
-
Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study - Nature
-
Pemphigus: Rituximab Shows Lower Cancer Risk Than Other Txs - Medscape
-
Topline Data Show Zanubrutinib Plus Rituximab Cut Risk of Progression or Death 43% Over BR in Frontline Treatment of MCL - The American Journal of Managed Care
-
Case Report: Relapsing systemic lupus erythematosus treated with dual rituximab and anifrolumab therapy - Frontiers
-
Long-Term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL - The American Journal of Managed Care
-
Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma - The ASCO Post
-
Ocrelizumab Leads to Lower Hospitalization Rates vs Rituximab in MS - The American Journal of Managed Care
-
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial - The Lancet
-
Intrathecal rituximab for the treatment of Epstein–Barr virus-associated encephalitis - Frontiers
-
Efficacy and safety of low-dose rituximab in MuSK antibody-positive myasthenia gravis: a single-center retrospective study - Frontiers
-
Rituximab Patients Should Guard Against Mosquito and Tick Bites as CDC Flags Risk of Severe Brain Infection - Medical Daily
-
Rituximab Lymph Node Injection Combined With Angioplasty for Fibrosing Mediastinitis | Annals of Internal Medicine - ACP Journals
-
Case report: Parvovirus B19 encephalitis following rituximab therapy in a patient with immune-mediated thrombocytopenia - Frontiers
-
AUGMENT phase III 5-year follow-up: Lenalidomide + rituximab in R/R iNHL - Lymphoma Hub
-
Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma - The ASCO Post
-
Rituximab-Associated Posterior Reversible Encephalopathy Syndrome in Severe Hydralazine-Induced Antineutrophil Cytoplasmic Antibody Vasculitis: An Unexpected Complication - Cureus
-
Successful Treatment With Rituximab for Severe Immune Thrombocytopenic Purpura During Hemodialysis - Cureus
-
Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting - Cureus
-
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - The ASCO Post
-
Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma - OncLive
-
Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line - The American Journal of Managed Care
-
Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review - Cureus
-
Orelabrutinib and rituximab regimen combined with intravitreal methotrexate for treatment of primary vitreoretinal lymphoma: a case report and literature review - Frontiers
-
CHESS phase II: Zanubrutinib + rituximab followed by shortened chemoimmunotherapy in 1L MCL - Lymphoma Hub
-
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL - The American Journal of Managed Care
-
Rituximab for the treatment of membranous nephropathy in a patient with ankylosing spondylitis: a case report - Frontiers
-
Staphylococcus aureus Pyogenic Spondylodiscitis in a Patient With Rheumatoid Arthritis Receiving Rituximab - Cureus
-
Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma - The ASCO Post
-
Rituximab: A New Hope for Adult-Onset Nephrotic Syndrome? - Medscape
-
Tafasitamab + lenalidomide + rituximab approved by Japan’s MHLW for R/R FL - Lymphoma Hub
-
Rituximab Therapy for Recalcitrant Idiopathic... : Ophthalmic Plastic & Reconstructive Surgery - Ovid
-
Phase 3 Data Suggest Bispecific May Replace Rituximab in DLBCL, but Toxicity Remains a Concern - Oncology News Central
-
Frontline Acalabrutinib/Rituximab Followed By Brexu-Cel Shows Synergy and Safety in High-Risk MCL - OncLive
-
Optimizing rituximab dosing for prolonged B-cell depletion in children with steroid-dependent nephrotic syndrome: impact of age and sex - Springer Nature Link
-
Preliminary Studies are Encouraging for Rituximab in MS - Neurology Today
-
Yearly Rituximab Dosing Shows Comparable Efficacy to Standard 6-Month Regimen in Relapsing-Remitting MS - NeurologyLive
-
Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma - OncLive
-
Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL - Lymphoma Hub
-
Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma - OncLive
-
Cost-effective rituximab-based treatment keeps CAD at bay for years - Cold Agglutinin Disease News
-
Considering Third-Line Loncastuximab Tesirine Plus Rituximab in Follicular Lymphoma - The American Journal of Managed Care
-
Maintenance Low-Dose BRAF Inhibition and Rituximab in Relapsed Hairy Cell Leukemia: A Therapeutic Alternative - Cureus
-
Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma - OncLive
-
SOUNDTRACK-F1: Early Deep Responses and Manageable Safety With Surovatamig + Rituximab in Frontline FL - Oncodaily
-
Polatuzumab vedotin plus rituximab with chemotherapy in newly diagnosed pediatric stage IV Burkitt lymphoma: case report highlighting early complete remission - Frontiers
-
Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma - OncLive
-
Rituximab Cuts ANCA Vasculitis Pneumococcal Vaccine Response - Medscape
-
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.